



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 12.11.2020

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001

Sub: Submission of Un-Audited Standalone And Consolidated Financial Results for quarter and half year ended 30th September, 2020 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Kindly find enclosed herewith the following:

1. A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the quarter and half year ended 30th September, 2020;

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED



NAMRATA KAMBLI
COMPANY SECRETARY AND COMPLIANCE OFFICER

Encl: As above

To

**The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022**

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Parnax Lab Limited** (“the company”) for the quarter and six months ended September 30, 2020 together with the relevant notes thereon (“the Statement”). The Statement being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

Vinod Ladha
(Vinod Ladha)

Partner

M. No. : 104151

Place : Mumbai

Dated : 12th November, 2020

UDIN : 20104151AAAACO2989



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN - L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2020


S. No.	Particulars	(Rs. in Lakhs)					
		Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
I	Revenue from operations	70.10	21.74	178.09	91.84	324.12	767.95
II	Other income	2.46	0.73	7.06	3.19	14.31	41.58
III	Total Revenue (I+II)	72.56	22.47	185.15	95.03	338.43	809.53
IV	Expenses						
	a) Cost of material consumed	19.81	0.08	52.96	19.89	103.21	260.55
	b) Purchase of stock in trade	17.48	15.57	55.21	31.05	89.27	170.55
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	-	-	-	-	-
	d) Employee benefit expenses	9.58	10.91	12.62	20.49	24.46	51.34
	e) Finance costs	22.03	21.72	70.41	43.75	95.20	137.85
	f) Depreciation and amortisation expenses	1.10	1.10	1.10	2.20	2.20	4.38
	g) Other expenses	19.88	10.31	51.11	30.19	94.71	232.06
	Total Expenses (IV)	89.88	59.69	243.41	149.57	409.05	856.73
V	Profit/(loss) before exceptional items and tax (III-IV)	(17.32)	(37.22)	(58.26)	(54.54)	(70.62)	(47.20)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(loss) before tax (V-VI)	(17.32)	(37.22)	(58.26)	(54.54)	(70.62)	(47.20)
VIII	Tax expense						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	153.25
	c) Short (Excess) provision for tax for earlier years	-	-	-	-	-	-
IX	Profit/(loss) for the period (VII-VIII)	(17.32)	(37.22)	(58.26)	(54.54)	(70.62)	(200.45)
X	Other comprehensive income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	0.45
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(0.12)
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XI	Total other comprehensive income for the period	-	-	-	-	-	0.33
XII	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	(17.32)	(37.22)	(58.26)	(54.54)	(70.62)	(200.12)
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIV	Earning per equity share (Not annualised)						
	(1) Basic	(0.20)	(0.44)	(0.69)	(0.64)	(0.83)	(2.36)
	(2) Diluted	(0.20)	(0.44)	(0.69)	(0.64)	(0.83)	(2.36)

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2020.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2020.
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and half year ended September 30, 2020.
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai
Date : 12-11-2020

By Order of the Board
For Parnax Lab Limited



Prakash M. Shah
Director & CEO
DIN : 00440980

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925

Statement of Assets and Liabilities as at 30th September, 2020

(Rs. in Lakhs)

S. No.	Particulars	Standalone		
		30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
A	ASSETS			
1	Non-Current Assets			
(a)	Property, plant and equipment	50.82	55.21	53.02
(b)	Capital work-in-progress	-	-	-
(c)	Investment Property	-	-	-
(d)	Other Intangible assets	0.06	0.06	0.06
(e)	Financial assets			
(i)	Investments	1,006.95	1,006.95	1,006.95
(ii)	Other non-current financial assets	5.34	5.34	5.34
(f)	Deferred tax assets (net)	106.02	259.39	106.02
2	Current Assets			
(a)	Inventories	15.24	22.08	15.05
(b)	Financial assets			
(i)	Investments	-	-	-
(ii)	Trade Receivables	104.50	191.79	206.30
(iii)	Cash and cash equivalents	33.07	20.17	10.79
(iv)	Bank balances other than above	1.20	1.11	1.20
(v)	Loans	2.38	2.59	2.48
(c)	Current tax assets (Net)	13.29	13.29	13.29
(d)	Other current assets	81.00	83.58	70.55
(e)	Assets classified as held for sale	374.05	372.73	374.05
	TOTAL - ASSETS	1,793.92	2,034.29	1,865.10
B	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	850.49	850.49	850.49
(b)	Other equity	(322.70)	(138.65)	(268.15)
2	Liabilities			
(I)	Non-current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	226.96	267.04	277.12
(b)	Provisions	1.32	1.27	1.32
(c)	Deferred tax liabilities (Net)	-	-	-
(d)	Other non-current liabilities	-	-	-
(II)	Current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	830.71	779.15	803.14
(ii)	Trade payables	92.44	156.00	104.02
(iii)	Other current financial liabilities	104.48	105.00	77.37
(b)	Other current liabilities	10.04	13.83	19.61
(c)	Short-term provisions	0.18	0.16	0.18
	TOTAL EQUITY AND LIABILITIES	1,793.92	2,034.29	1,865.10

By Order of the Board
For Parnax Lab Limited



Prakash M Shah
Director & CEO
DIN : 00440980

Mumbai
Date : 12-11-2020

PARNAX LAB LIMITED
Standalone Cash Flow Statement for the period ended 30th September, 2020

Particulars	(Rs. in Lakhs)		
	For the period ended 30th September, 2020 (Unaudited)	For the period ended 30th September, 2019 (Unaudited)	For the year ended 31st March 2020 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit/(Loss) before tax	(54.54)	(70.62)	(47.20)
Adjustments for			
Depreciation	2.20	2.20	4.38
Finance Costs	43.75	95.20	137.85
Loss on sale of Property, plant & equipments	-	-	0.34
Sundry Balances written off	-	0.40	0.40
Interest & Dividend income	-	(0.09)	(0.56)
Operating Loss Before Working Capital Adjustments	(8.59)	27.09	95.21
Changes in Working Capital			
<u>Adjustments for (increase) / decrease in operating assets:</u>			
Inventories	(0.20)	19.69	26.73
Trade receivables	101.80	58.55	44.05
Other assets (Financials and Non Financial assets)	(10.35)	(2.64)	10.89
<u>Adjustments for increase / (decrease) in operating liabilities:</u>			
Trade payables	(11.58)	68.65	16.27
Other liabilities (Financials and Non Financial assets)	(27.12)	9.23	24.87
Cash generated from operations	43.96	180.57	218.02
Direct Tax Paid (Refund) [Net]	-	(1.50)	(1.50)
Net cash flow from / (used in) operating activities (A)	43.96	182.07	219.52
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant & equipment	-	-	(4.66)
Proceeds from sale of fixed assets	-	-	3.00
Proceeds/(Purchase) from sale of Non Current Investments	-	-	-
Interest & Dividend income	-	0.09	0.47
Net cash flow from / (used in) investing activities (B)	-	0.09	(1.19)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from borrowings (net)	22.07	(74.31)	(16.70)
Finance Cost	(43.75)	(34.69)	(137.85)
Net cash flow from / (used in) financing activities (C)	(21.68)	(109.00)	(154.55)
Net increase (decrease) in cash and cash equivalents (A+B+C)	22.28	73.16	63.78
Cash and cash equivalents at the beginning of the year	10.79	(52.99)	(52.99)
Cash and cash equivalents at the end of the year	33.07	20.17	10.79

By Order of the Board
For Parnax Lab Limited



Prakash M Shuh
Prakash M Shuh
Director & CEO
DIN : 00440980

Mumbai
Date : 12-11-2020

To

**The Board of Directors,
Parnax Lab Limited,**

114, Building No. 8, Jogani Industrial Complex,
Chunabhatti, Mumbai - 400 022

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** ("the Parent") and **Naxpar Pharma Private Limited** ("the Subsidiary") (the Parent and its subsidiary together referred to as "the Group") for the quarter and six months ended September 30, 2020 together with the relevant notes thereon ("the Statement"). The Statement submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. The Statement is the responsibility of the Parent's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended, to the extent applicable.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants
(FRN: 120241W)

Vinod Ladha
(Vinod Ladha)

Partner

M. No. : 104151

Place : Mumbai

Dated : 12th November, 2020

UDIN : 20104151AAAACP5847



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2020

(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
I	Revenue from operations	2,674.99	1,746.16	2,570.39	4,421.15	4,636.74	9,531.48
II	Other income	6.34	2.66	9.04	9.00	16.54	66.23
III	Total Revenue (I+II)	2,681.33	1,748.82	2,579.43	4,430.15	4,653.28	9,597.71
IV	Expenses						
	a) Cost of material consumed	1,125.90	824.24	1,174.57	1,950.14	2,073.68	4,529.59
	b) Purchase of stock in trade	(20.16)	47.64	78.36	27.48	85.38	87.97
	c) Changes in inventories of finished goods, Work in progress and stock in trade	64.28	(32.06)	(38.85)	32.22	-	(90.34)
	d) Employee benefit expenses	330.43	269.99	335.85	600.42	693.74	1,407.98
	e) Finance costs	129.76	124.96	138.37	254.72	239.86	460.18
	f) Depreciation and amortisation expenses	130.94	122.80	107.30	253.74	212.97	445.94
	g) Other expenses	680.55	368.02	747.96	1,048.57	1,304.46	2,953.12
	h) Impairment of assets classified as held for disposal						
	Total Expenses (IV)	2,441.70	1,725.59	2,543.56	4,167.29	4,610.09	9,794.44
V	Profit/(loss) before exceptional items and tax (III-IV)	239.63	23.23	35.87	262.86	43.19	(196.73)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	239.63	23.23	35.87	262.86	43.19	(196.73)
VIII	Tax expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	98.49
	c) Short (Excess) Prov for Tax for Earlier Years	-	-	-	-	(4.40)	(3.61)
IX	Profit/ (Loss) for the period (VII-VIII)	239.63	23.23	35.87	262.86	47.59	(291.61)
X	Minority Interest Profit (Loss)	0.12	0.12	0.20	0.63	0.24	(0.18)
XI	Profit/ (Loss) after share of Profit (Loss) of Minority Interest	239.51	23.11	35.67	262.23	47.35	(291.43)
XII	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						(2.87)
	(ii) Income tax relating to items that will not be reclassified to profit or loss						0.75
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XIII	Total Other Comprehensive Income for the period	-	-	-	-	-	(2.12)
XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	239.51	23.11	35.67	262.23	47.35	(293.55)
XV	Total profit/(loss) for the year attributable to:						
	- Owners of the Company	239.00	23.23	35.67	262.23	47.35	(291.43)
	- Non-controlling interests	0.51	0.12	0.20	0.63	0.24	(0.18)



 Mumbai

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
XVI	Other Comprehensive income attributable to :						
	- Owners of the Company		-	-	-	-	(2.12)
	- Non-controlling interests		-	-	-	-	(0.01)
XVII	Total Comprehensive income attributable to:						
	- Owners of the Company	239.00	23.23	35.67	262.23	47.35	(293.54)
	- Non-controlling interests	0.51	0.12	0.20	0.63	0.24	(0.19)
XVIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIX	Earning per equity share (Not Annualised)						
	(1) Basic	2.82	0.27	0.42	3.09	0.56	(3.43)
	(2) Diluted	2.82	0.27	0.42	3.09	0.56	(3.43)

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2020.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2020
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business , including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter -alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and half year ended September 30, 2020.
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai
Date : 12-11-2020



By Order of the Board
For Parnax Lab Limited


Prakash M Shah
Director & CEO
DIN NO: 00440980


PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925

Statement of Consolidated Assets and Liabilities as at 30th September, 2020

S. No.	Particulars	Consolidated		
		30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
(Rs. in Lakhs)				
A	ASSETS			
1	Non-Current Assets			
(a)	Property, plant and equipment	5,612.60	4,899.24	5,673.44
(b)	Right-of-use asset	72.53	-	73.77
(c)	Capital work-in-progress	319.31	238.58	291.40
(d)	Other Intangible assets	17.35	23.91	20.60
(e)	Financial assets			
(i)	Investments	22.46	21.46	22.46
(ii)	Other non-current financial assets	42.23	43.04	48.45
(f)	Deferred tax assets (net)			-
(g)	Other non-current assets	22.95	5.00	22.95
2	Current Assets			
(a)	Inventories	1,221.45	977.24	1,115.11
(b)	Financial assets			
(i)	Trade Receivables	2,022.85	2,082.39	2,308.42
(ii)	Cash and cash equivalents	54.24	18.09	38.68
(iii)	Bank balances other than above	100.95	84.68	90.95
(iv)	Loans	56.18	76.69	60.07
(c)	Current tax assets (Net)	226.86	148.76	196.93
(d)	Other current assets	305.47	253.32	377.14
(e)	Assets classified as held for sale	374.05	372.73	374.05
	TOTAL - ASSETS	10,471.48	9,245.13	10,714.42
B	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	850.49	850.49	850.49
(b)	Other equity	2,685.53	2,769.91	2,429.02
	Equity attributable to owner	3,536.02	3,620.40	3,279.51
	Non Controlling Interest	13.84	7.92	7.50
	Total Equity	3,549.86	3,628.32	3,287.01
2	Liabilities			
(I)	Non-current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	1,656.10	1,775.14	1,915.30
(ii)	Lease Liabilities	71.04	-	72.00
(b)	Provisions	26.91	28.91	26.91
(c)	Deferred tax liabilities (Net)	168.94	71.19	168.94
(II)	Current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	3,136.93	2,213.09	2,811.39
(ii)	Trade payables	597.77	371.95	1,084.13
(iii)	Lease Liabilities	1.91	-	1.91
(iv)	Other current financial liabilities	1,218.93	1,040.93	1,251.70
(b)	Other current liabilities	40.31	113.07	91.83
(c)	Short-term provisions	2.78	2.53	3.30
	Total Liability	6,921.62	5,616.81	7,427.41
	TOTAL EQUITY AND LIABILITIES	10,471.48	9,245.13	10,714.42

By Order of the Board
For Parnax Lab Limited


Prakash M Shah
Director & CEO
DIN NO: 00440980

Mumbai
Date : 12-11-2020

PARNAX LAB LIMITED
Consolidated Cash Flow Statement for the period ended 30th September, 2020

Particulars	(Rs. in Lakhs)		
	For the period ended 30th September, 2020 (Unaudited)	For the period ended 30th September, 2019 (Unaudited)	For the year ended 31st March 2020 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit/(Loss) before tax	262.86	43.19	(196.73)
Adjustments for			
Depreciation	253.74	212.97	445.94
Finance Cost	254.72	239.86	460.18
Loss/(Profit) on sale of Property, plant & equipments	(1.06)	-	0.34
Sundry Balances written off	(0.03)	0.52	(0.45)
Interest & Dividend income	-	(1.12)	(8.95)
Operating Loss Before Working Capital Adjustments	770.23	495.42	700.33
Changes in Working Capital			
<u>Adjustments for (increase) / decrease in operating assets:</u>			
Inventories	(106.33)	(130.20)	(268.08)
Trade receivables	285.57	(254.81)	(392.14)
Other assets (Financials and Non Financial assets)	81.75	644.53	534.47
<u>Adjustments for increase / (decrease) in operating liabilities:</u>			
Trade payables	(486.33)	(263.06)	360.88
Other liabilities (Financials and Non Financial assets)	(130.44)	(174.18)	44.40
Cash generated from operations	414.45	317.70	979.86
Direct Tax Paid (Refund) [Net]	29.93	58.25	107.23
Net cash flow from / (used in) operating activities (A)	384.52	259.45	872.63
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant & equipment	(194.13)	(255.00)	(1,034.29)
Expenditure on capital work in progress	(27.91)	-	(277.25)
Expenditure on asset held for disposal	-	-	(4.66)
Investment in fixed deposit	(10.00)	-	(26.13)
Proceeds from sale of fixed assets	6.80	-	3.00
Proceeds/(Purchase) from sale of Non Current Investments	-	-	(1.00)
Interest & Dividend income	-	1.12	8.86
Net cash flow from / (used in) investing activities (B)	(225.24)	(253.88)	(1,331.47)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from borrowings (net)	110.99	197.06	962.89
Finance Cost	(254.72)	(179.35)	(460.18)
Net cash flow from / (used in) financing activities (C)	(143.73)	17.71	502.71
Net increase (decrease) in cash and cash equivalents (A+B+C)	15.55	23.28	43.87
Cash and cash equivalents at the beginning of the year	38.68	(5.19)	(5.19)
Cash and cash equivalents at the end of the year	54.23	18.09	38.68

Mumbai
Date : 12-11-2020



By Order of the Board
For Parnax Lab Limited

Prakash M. Shah
Prakash M. Shah
Director & CEO
DIN : 00440980